Table 8.
Summary of Preclinical In Vivo Models from the Past Decade Used to Evaluate the Treatment of Orthopedic Implant-Associated Infections with Antimicrobial Agents and Biomaterials
| models to evaluate treatment of implant-associated infections | |||||||
|---|---|---|---|---|---|---|---|
| animal model | implant/location | pathogen | antimicrobial agent | study duration | key evaluation | summary | ref |
| mice – BALB/C | titanium in femur | S. aureusATCC | gentamicin, vancomycin (local, sustained) | 6 weeks | (1) CFU counts | antibiotic calcium sulfate/hydroxyapatite spacer for infection treatment | 247 |
| 292131.35 × 105 CFU | (2) collect blood | ||||||
| (3) X-rays | |||||||
| mice – BALB/C | poly(ether ether ketone) and titanium in femur | S. aureus Xen 36 | vancomycin, rifampin (local, sustained) | 1 week infection | (1) CFU count | 3D printed calcium phosphate and PMMA antibiotic spacers for infection treatment | 118 |
| 8 × 104 CFU | 3 weeks antibiotics | (2) in vivo BLI | |||||
| (3) X-rays | |||||||
| (4) micro-CT | |||||||
| (5) SEM biofilm | |||||||
| mice – BALB/C | poly(ether ether ketone) and titanium in femur | S. aureus Xen 36 | vancomycin (local, sustained) | 1 week infection | (1) CFU count | antibiotic PMMA spacers for infection treatment | 119 |
| 8 × 104 CFU | 3 weeks antibiotics | (2) in vivo BLI | |||||
| (3) micro-CT | |||||||
| mice – BALB/C | titanium in femur | S. aureus Xen 36 | gentamicin (local, sustained) | 1 week infection | (1) CFU count | antibiotic PMMA spacers for infection treatment | 126 |
| 2.5 × 106 CFU | 2 weeks antibiotics | (2) X-rays | |||||
| (3) in vivo BLI | |||||||
| mice – BALB/C | stainless steel in tibia | S. aureus UAMS-1 | cefazoline, gentamicin, vancomycin, rifampin (systemic) | 1 week infection | (1) CFU count | evaluation of combination antibiotics for treatment of implant biofilms | 248 |
| 2.5 × 105 CFU | 2 weeks antibiotics | (2) SEM biofilm | |||||
| (3) histology | |||||||
| mice – C57Bl/6 | titanium in femur | MRSA USA 300 | linezolid, rifampin, vancomycin, daptomycin (systemic) | 2 weeks infection | (1) CFU count | evaluation of combination antibiotics for treatment of implant infection | 249 |
| 1 × 103 CFU | 6 weeks antibiotics | (2) in vivo BLI | |||||
| (3) X-rays | |||||||
| (4) micro-CT | |||||||
| mice – C57Bl/6 | titanium in tibia | S. aureus Xen 36 | vancomycin (local, sustained) | 2 weeks infection | (1) CFU count | antibiotic PMMA spacers for infection treatment, need for intravenous antibiotics | 127 |
| 3 × 105 CFU | 4 weeks antibiotics | (2) collect blood | |||||
| (3) X-rays | |||||||
| rats – Sprague–Dawley | Kirschner wire in tibia | MRSA 40496/08 | dalbavancin, vancomycin (systemic) | 4 weeks | (1) CFU count | antibiotics for implant MRSA infection treatment | 250 |
| 1–5 × 106 CFU | (2) X-rays | ||||||
| rats – Sprague–Dawley | intramedullary implant in tibia | S. aureus EDCC 5055 | none | 6 weeks | (1) CFU count | use of CpG oligodeoxynucleotide to treat implant infections | 251 |
| 1 × 103 CFU | (2) histology | ||||||
| rats – Sprague–Dawley | Kirschner wire in tibia | MRSA N315 | vancomycin (local, sustained) | 2 weeks infection | (1) CFU count | antibiotic silicone cement for treatment of implant infection | 260 |
| 1 × 108 CFU | 4 weeks antibiotics | (2) X-rays | |||||
| (3) histology | |||||||
| rats – Sprague–Dawley | PMMA in tibia | MRSA ATCC 25923 | fusidic acid (local, sustained), teicoplanin (systemic) | 3 weeks infection | (1) CFU count | antibiotic cement with systemic antibiotics for treatment of implant infection | 131 |
| 5 × 105 CFU | 2 weeks antibiotics | (2) histology | |||||
| rats – Sprague–Dawley | alginate-hyaluronic acid in femur | S. aureus KCTC1621 | vancomycin (local, sustained) | 2 weeks infection | (1) CFU count | in situ gelling hydrogel for treatment of implant infections | 85 |
| 1 × 104 CFU | 3 and 6 weeks antibiotics | (2) micro-CT | |||||
| (3) collect blood | |||||||
| (4) X-rays | |||||||
| rats – Sprague–Dawley | injectable alginate hydrogel in femur | S. aureus ATCC 6538 | fosfomycin (local, sustained) | 1 week infection | (1) CFU count | injectable antibiotic hydrogel and bacteriophage for treatment of implant infections | 105 |
| 5 × 104 CFU | 1 week antibiotics | (2) SEM | |||||
| (3) histology | |||||||
| rats – Sprague–Dawley | silver nanoparticles in gelatin sponge in tibia | MRSA ATCC 43300 | teicoplanin (local sustained) | 3 weeks infection | (1) X-ray | silver nanoparticles for treatment of implant infections | 252 |
| 1 × 107 CFU | 3 weeks antibiotics | (2) collect blood | |||||
| rats – Wistar | stainless steel in femur | S. aureus ATCC 29213 | moxifloxacin, flucloxacillin, rifampin, vancomycin (systemic) | 1 week infection | (1) CFU count | evaluation of combination antibiotics for treatment of implant infection | 253, 254 |
| 1 × 108 CFU | 2 weeks antibiotics | ||||||
| rats – Wistar | collagen sponge and PMMA beads in tibia | S. aureus ATCC 292113 | gentamicin, cefazolin (local, sustained) | 3 weeks infection | (1) CFU count | comparison of antibiotic carrier for treatment of implant infections | 86 |
| 5 × 106 CFU | 2 or 4 weeks antibiotics | ||||||
| rats – Wistar | poly(d-l-lactide-co-glycolide-co-ε-capro-lactone) in tibia | S. aureus | ciprofloxacin (local, sustained) | 4 weeks infection | (1) CFU count | antibiotic poly(d-l-lactide-co-glycolide-co-ε-caprolactone) implant coating to treat infections | 255 |
| 1 × 108 CFU | 4 weeks antibiotics | (2) collect blood | |||||
| rats – Wistar | magnetite encapsulated gelatin particles in tail vein | S. aureus | gentamicin (local, sustained) | 2 weeks infection | (1) X-rays | magnetite antibiotic particles for treatment of implant infection | 25 |
| 1 × 109 CFU | 2 weeks antibiotic | (2) collect blood | |||||
| (3) histology | |||||||
| rats – Long-Evans | titanium in humerus | MRSA NR0 | vancomycin (systemic) | 6 day infection | (1) CFU count | electrical stimulation with antibiotics to treat implant infection | 27 |
| 1 × 105 CFU | 5 weeks antibiotics | (2) X-rays | |||||
| (3) histology | |||||||
| rabbits – New Zealand White | silicone elastomer in tibia | MRSA S271 ST20121238 | daptomycin, rifampin, ceftaroline (systemic) | 1 week infection | (1) CFU count | evaluation of combination antibiotics for treatment of MRSA implant infection | 256, 257 |
| 5 × 107 CFU | 10 days antibiotics | ||||||
| rabbits – New Zealand White | stainless steel in tibia | MRSA EDCC 5443 EDCC 5398 | vancomycin (local, sustained) | 4 weeks infection | (1) CFU count | antibiotic PMMA spacer for two-stage implant infection revision | 132 |
| 1 × 105–1 × 107 CFU | 4 weeks antibiotics | (2) X-rays | |||||
| (3) histology | |||||||
| rabbits – New Zealand White | Ti6Al4 V in femur | S. aureus ATCC 29213 | gentamicin (local, sustained) | 1 week infection | (1) CFU count | antibiotic PMMA chain for treatment of implant infection (copper and titanium oxide coated) | 133 |
| 1 × 105 CFU | 2 weeks antibiotics | (2) collect blood | |||||
| rabbits – New Zealand White | borate bioactive glass in tibia | MRSA ATCC 43300 | vancomycin (local, sustained) | 8 weeks | (1) CFU count | injectable borate bioactive glass for treating implant infection | 30 |
| 1 × 108 CFU | (2) collect blood | ||||||
| (3) X-rays | |||||||
| (4) histology | |||||||
| rabbits – New Zealand White | calcium sulfate in tibia | S. aureus ATCC 29213 | gentamicin (local, sustained) | 2 weeks infection | (1) CFU count | antibiotic calcium sulfate to treat implant infection | 28 |
| 2 × 106 CFU | 2 weeks antibiotics | (2) X-rays | |||||
| (3) collect blood | |||||||
| rabbits – New Zealand White | PLGA in femur | S. aureus ATCC 65389 | vancomycin (local, sustained) | 2 weeks infection | (1) CFU count | monitor treatment of implant infections with 18F-FDG-PET imaging | 35 |
| 1 × 105 CFU | 2 weeks antibiotics | (2) 18F-FDG-PET imaging | |||||
| rabbits – New Zealand White | Hydroxyapatite–polyamino acid in tibia | S. aureus | vancomycin (local, sustained) | 2 weeks infection | (1) CFU counts | antibiotic hydroxyapatite/polyamino acid for treatment of implant infection and osteogenesis | 235 |
| 1 × 108 CFU | 6 weeks antibiotics | (2) X-ray | |||||
| (3) collect blood | |||||||
| (4) histology | |||||||
| rabbits – New Zealand White | stainless steel with silver particles in femur | S. aureus ATCC 29213 | none | 3 weeks infection | (1) CFU count | silver nanoparticle implant coating to treat infections | 258 |
| 3 × 106 CFU | 3 weeks treatment | (2) X-rays | |||||
| (3) histology | |||||||
| (4) SEM | |||||||
| rabbits – New Zealand White | Hydroxyapatite–polyamino acid PLGA in tibia | S. aureus ATCC 25923 | rifapentine (local, sustained) | 4 weeks infection | (1) CFU count | antibiotic composite material for treatment of implant infection | 106 |
| 3 × 108 CFU | 4 weeks antibiotics | (2) collect blood | |||||
| (3) X-rays | |||||||
| (4) histology | |||||||
| (5) gait analysis | |||||||
| rabbits – New Zealand White | chitosan thermosensitive hydrogel in tibia | S. aureus Kanin | vancomycin (local, sustained) | 4 weeks infection | (1) collect blood | injectable thermosensitive hydrogel with quaternary ammonium chitosan for treatment of implant infections | 24 |
| 1 × 108 CFU | 4–8 weeks antibiotics | (2) micro-CT | |||||
| (3) histology | |||||||
| dogs – Beagle | stainless steel in femur | S. aureus ATCC 29213 | ciprofloxacin (local, sustained) | 4 weeks infection | (1) CFU count | amylose starch antibiotic coated implants to treat infection | 259 |
| 3 × 108 CFU | 6 weeks antibiotics | (2) X-rays | |||||
| (3) histology | |||||||